HomeAboutMedical Tourism
GeorgiaTurkeyUAESwitzerlandChina
Medical Family OfficeOne-Time ServiceContactBook a consultationChat on WhatsApp (opens in a new tab)
Medical Tourism · China

China

China is a global pioneer in CAR-T cell therapy and one of the most advanced destinations for precision oncology. Delegata arranges treatment there on request, at top-tier, internationally accredited university hospitals in Beijing and Shanghai, from physician review of your records to admission, interpretation and follow-up.

CAR-T cell therapyProton and heavy-ion therapyJCI-accredited centresBeijing and ShanghaiArranged on request
Book a consultation
Consultation fee AED 300
All destinations
Overview

Treatment in China: global leadership in advanced oncology and precision medicine

China has rapidly emerged as one of the world's most advanced destinations for cutting-edge biomedicine, clinical innovation and specialised healthcare. For patients seeking breakthrough treatments that may not yet be widely available or approved in Western markets, China offers world-class, JCI-accredited centres equipped with pioneering technology and unmatched clinical volume.

The frontier of cancer care: CAR-T therapy

China is a global pioneer in CAR-T therapy (chimeric antigen receptor T-cell therapy), a revolutionary form of immunotherapy that reprogrammes a patient's own immune cells to precisely target and destroy cancer cells.

How it works: Your T cells are extracted, genetically re-engineered in an advanced laboratory to recognise specific cancer markers, and infused back into your body to fight the disease from within.

Why China leads: Chinese hospitals have conducted a massive share of the world's CAR-T clinical trials, building extensive real-world experience across haematological malignancies, including leukaemia, lymphoma and multiple myeloma. They are also advancing promising trials for solid tumours, such as gastric adenocarcinoma, glioblastoma, hepatocellular carcinoma and neuroblastoma.

Accessibility and speed: Due to streamlined regulatory pathways and state-of-the-art biotech infrastructure, patients can access approved and trial-phase cell therapies significantly faster than in many other regions, without compromising on stringent safety standards.

Through Delegata, your journey to China is fully coordinated, physician-vetted and managed with full transparency and close attention to safety.

Advanced therapies

Other advanced therapies available in China

Beyond immunotherapy, China's premier hospitals excel in several specialised, high-tech fields.

Precision proton and heavy-ion therapy

Advanced radiation oncology that targets deep-seated or complex tumours with pinpoint accuracy while sparing the healthy tissue around them.

Next-generation immunotherapies and combination trials

Access to novel checkpoint inhibitors and personalised vaccine therapies tailored to individual genetic profiles.

AI-driven diagnostics and robotic surgery

State-of-the-art surgical robotics and artificial intelligence diagnostics that shorten recovery times and maximise precision in complex procedures.

Regenerative medicine and cell therapies

Groundbreaking research and clinical applications in tissue repair and degenerative conditions.

China with Delegata

Why choose China with Delegata?

Navigating a foreign healthcare system, especially with a complex or critical diagnosis, can be overwhelming. Delegata acts as your personal medical family office, bridging the gap between you and China's elite hospitals.

Physician-led oversight

As a physician-founded organisation, we personally review your records, vet your case, and match you with the exact sub-specialist and hospital best suited to your condition.

End-to-end concierge support

We handle every detail, from secure translation of your records and second opinions to VIP hospital admission, specialised travel logistics and dedicated local interpreters.

Quality and safety first

We partner exclusively with top-tier, internationally accredited university hospitals in hubs such as Beijing and Shanghai, ensuring uncompromising standards of clinical care.

Questions about treatment in China

What clients ask about China

Who can be considered for CAR-T therapy in China?

CAR-T is used mainly for blood cancers, such as certain leukaemias, lymphomas and multiple myeloma, usually when earlier treatment has not worked. For solid tumours it is mostly available through clinical trials. Eligibility depends on your diagnosis, previous treatment and current health, so a Delegata physician reviews your records before any hospital is approached.

How long does CAR-T treatment in China take?

Plan for roughly two to three months in China. Your T cells are collected, the therapy is manufactured over one to four weeks, and it is infused after a short course of chemotherapy. You then stay near the hospital for about four weeks of close monitoring. The hospital confirms the exact schedule for your case.

Is CAR-T therapy in China safe?

CAR-T is a powerful treatment with known serious side effects, such as cytokine release syndrome and neurological effects, so it should only be given by an experienced team that can manage them. Delegata works with top-tier, internationally accredited university hospitals and confirms the treating team, plan and price in writing before you travel.

Do I need a visa to travel to China for treatment?

It depends on your nationality and on how long you will stay. China has widened visa-free entry for many passports, but treatment often lasts longer than a visa-free stay allows. Delegata checks the rules for your passport and handles the paperwork, including any invitation letter the hospital needs to issue.

In brief

Why consider China for advanced cancer treatment?

Short answer. China is a global pioneer in CAR-T cell therapy and runs a large share of the world's CAR-T clinical trials. Its leading hospitals also offer proton and heavy-ion therapy, next-generation immunotherapy and robotic surgery. Delegata arranges treatment on request at top-tier, internationally accredited university hospitals in Beijing and Shanghai.

Patients often look to China for treatments that are not yet widely available or approved in Western markets. Streamlined regulatory pathways mean approved and trial-phase cell therapies can be reached faster than in many other regions. CAR-T is used mainly for blood cancers such as leukaemia, lymphoma and multiple myeloma, and trials are under way for solid tumours. Not every patient is a candidate. A Delegata physician reviews your records first and says plainly if another option suits you better.

How does Delegata arrange treatment in China?

Short answer. A Delegata physician reviews your records, then matches your case to the right sub-specialist and hospital. You receive the plan, timeline and price in writing before you commit. Delegata then coordinates translation of your records, admission, travel, visa paperwork and a local medical interpreter, and stays in touch after you return home.

The first step is a 30-minute consultation with a physician advisor, from AED 300, credited toward the arrangement fee. Delegata's own fee is confirmed in writing and kept separate from hospital costs. Treatment such as CAR-T usually means a stay of several weeks near the hospital, so Delegata plans accommodation for you and a companion. Clinical responsibility stays with the treating doctors. Delegata coordinates, advocates and keeps your records private.

Is treatment in China safe?

Short answer. At the right hospital, yes, but CAR-T itself carries known serious side effects, such as cytokine release syndrome and neurological effects. It should only be given by an experienced team that can manage them. Delegata works only with top-tier, internationally accredited university hospitals in Beijing and Shanghai and confirms the treating team in writing.

JCI accreditation is an international standard for hospital quality and patient safety. A Delegata physician reviews your case before any hospital is proposed and checks that the treatment fits your diagnosis and history. You see the team, the plan and the price in writing first. A local medical interpreter stays with you during admission and key appointments. After you return home, Delegata relays questions to the treating team and arranges follow-up. If treatment in China is the wrong answer, Delegata says so.

Accreditation source: Joint Commission International (JCI) (opens in a new tab)

In a world where healthcare can feel cold and complicated, I stand for bringing empathy, efficiency and clarity to the process of healing. After more than a decade as a radiologist and oncologist, I founded Delegata to address something I witnessed repeatedly: patients navigating fragmented healthcare systems alone, despite seeking the very best care.

Dr Madina Khadartseva, MD, PhD, Founder & CEO

Ready to explore treatment in China?

Take control of your health journey with confidence. Contact the Delegata team today to discuss whether advanced therapies in China are right for you or a loved one.

Medically reviewed by

Dr Madina Khadartseva, MD, PhD

Founder & CEO · Radiologist and oncologist

Last updated · LinkedIn (opens in a new tab) · How we review content